Adam J. Fein

@DrugChannels

Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. Contact me at afein@drugchannels.net

Philadelphia, PA
DrugChannels.net
Vrijeme pridruživanja: ožujak 2009.
762 fotografije ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @DrugChannels

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DrugChannels

  1. prije 32 minute

    Vertical integration update: partners with private equity firm for "senior-focused, payor-agnostic, primary care centers" for patients More $$ = greater control over patient access, sites of care/dispensing, and pricing

    4 korisnika označavaju da im se sviđa
    Poništi
  2. prije 4 sata

    Thought-provoking analysis from : Can an inflation cap on drugs be inflationary? Sorry, folks. The law of unintended consequences has not been repealed.

    4 proslijeđena tweeta 14 korisnika označava da im se sviđa
    Poništi
  3. 4. velj

    New Enrollment Data for 2020 Preferred Pharmacy Networks: Holds Steady, Rebounds, and Tanks

    4 proslijeđena tweeta 5 korisnika označava da im se sviđa
    Poništi
  4. 3. velj

    From : Nice (but super short) profile of and its business

    2 korisnika označavaju da im se sviđa
    Poništi
  5. 3. velj

    The World Congress 8th Annual Patient Congress

    Poništi
  6. 2. velj

    Must read in : How Chaos at Chain Is Putting Patients at Risk Pharmacists cite "understaffed and chaotic workplaces" & risk of medication errors. DCI data show busier chain locations. No wonder VCs are funding alternatives.

    9 proslijeđenih tweetova 20 korisnika označava da im se sviđa
    Poništi
  7. 31. sij

    Heads up! reverses 2019 rule, proposes giving plans option to use w/o regard to whether has generic equivalent (§156.130) Very patient unfriendly move, esp. for P.S. My $0.02:

    8 proslijeđenih tweetova 7 korisnika označava da im se sviđa
    Poništi
  8. 31. sij

    Wow. VCs really love the business. just invested $250 million in . Company has now raised nearly $400M. Crazy.

    2 proslijeđena tweeta 9 korisnika označava da im se sviđa
    Poništi
  9. 31. sij

    Per : allegedly reimbursed at rates two-thirds lower than rates Humana paid other profiteering never ends! "Two tier pricing" enables large, for-profit companies to grab $$$.

    1 reply 1 proslijeđeni tweet 5 korisnika označava da im se sviđa
    Poništi
  10. 30. sij

    FYI: plans to collect information from that support qualified health plans in marketplaces / exchanges. Data include , discounts, fees, network spreads, and more

    1 reply 5 proslijeđenih tweetova 10 korisnika označava da im se sviđa
    Poništi
  11. 30. sij

    Well done profile of new Health location & company's plans for primary care. But why was at the opening? Perhaps greater consumption of = more demand for ?

    1 reply 12 korisnika označava da im se sviđa
    Poništi
  12. 30. sij

    An ignoble end: exits troubled business have written down billions after unsuccessful diversification. Who's next? and medsurg? for int'l & ? 🤔

    1 reply 2 proslijeđena tweeta 5 korisnika označava da im se sviđa
    Poništi
  13. 29. sij

    Kudos to for RxZERO (no OOP for drugs) This is a broken market! - Drugs sold to at -54% discount 😲 - "clients opt to keep rebates" 🙄 - Patients pay OOP on pre-rebate list price & are less adherent 🙁

    5 replies 8 proslijeđenih tweetova 25 korisnika označava da im se sviđa
    Poništi
  14. 29. sij

    Retail shakeout update: highlights competitive challenges facing of regional chains P.S. Thanks for relying on data!

    5 proslijeđenih tweetova 9 korisnika označava da im se sviđa
    Poništi
  15. 28. sij

    Ugh. funded propaganda from . Data are *not* "Part D spending." Insulin is highly rebated. List prices going up, but net prices going down, e.g., Lantus (below), Humalog () P.S. "Before rebates" disclaimer ≠ accuracy

    7 proslijeđenih tweetova 11 korisnika označava da im se sviđa
    Poništi
  16. 28. sij

    Latest from Ronny Gal at Bernstein: Biosimilars' market shares rising & prices dropping. Actual net prices even lower b/c excludes discounts and rebates. breakthrough in 2020 (Sorry, full report available only from Bernstein)

    1 reply 10 proslijeđenih tweetova 25 korisnika označava da im se sviđa
    Poništi
  17. 28. sij

    Biosimilar competition update: is launching its 3 at WAC list prices of -22% to -24% below competitors' products Open question: Will , , and embrace or block lower price ?

    11 proslijeđenih tweetova 15 korisnika označava da im se sviđa
    Poništi
  18. 28. sij

    Drug Channels News Roundup, January 2020: ESI/Walgreens Breakup, Amazon Pharmacy, Humira’s G2N, Generic Prices, ABC's CEO, and Miss America

    2 korisnika označavaju da im se sviđa
    Poništi
  19. 27. sij

    Thanks to for covering my analysis of ICYMI: Manufacturers offer drugs with lower list prices, but Part D plans prefer therapeutically equivalent but higher-priced versions 🤔

    2 proslijeđena tweeta 5 korisnika označava da im se sviđa
    Poništi
  20. 27. sij

    From : Useful summary of state's nonsensical "transparency" laws. Most require "disclosure" of WAC list prices - which are already publicly available from multiple sources. 🙄

    Poništi

@DrugChannels još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·